English (UK)
中文版Roby Chen
Humanwell is the market leader in anaesthetics/analgesics, fertility regulation drugs, and Uyghur medicine in Asia. It is also a major player with expanding product portfolio and market shares in treating central nerve system, respiratory and dermatological diseases in China.
Humanwell Healthcare
投资部经理Kevin Chen
Wuxi Xinwu District
Wuxi international life science innovation campus
Investment promotion managerDenise Chen
GIG, one of the leading healthcare investment institute, was founded in Shenzhen in 2001. AUM is RMB ￥20b. It has invested in 80+ healthcare companies. 22 went IPO. GIG has 90+ staff in team with operating offices in Shenzhen, Shanghai, Beijing, Nanjing and Hongkong.
GIG
PartnerPaul Chen
Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global Phase II trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.
Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Currently we are looking for either partnership to develop the AD and/or UC or CD indications for Phase III or out-license the global right excluding China market.
Reistone Biopharma
Chief of StaffMr. Mark Chen
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialization of “best-in-class” and “first-in-class” innovative drugs and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. On 22 May 2020, Kintor Pharmaceuticals was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Kintor Pharmaceuticals
BD DirectorHaipeng Cheng
Sangel Capital provides venture capital and business finance to support high-tech enterprises in China and US. The firm seeks to invest in innovative startups in sectors including biopharma, diagnostics, medical devices, and biotech.
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.
Sangel Capital
Mr. Chris Chow
Hong Kong Biotechnology Organization is an independent nonprofit organization with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.
Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.
Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.
Responsive Web Design powered by 